Welgene Biotech Co.,Ltd. (6661.TWO)

TWD 19.2

(2.95%)

EBITDA Summary of Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.'s latest annual EBITDA in 2023 was 26.83 Million TWD , down -28.38% from previous year.
Welgene Biotech Co.,Ltd.'s latest quarterly EBITDA in 2024 Q2 was 6.26 Million TWD , up 190.69% from previous quarter.
Welgene Biotech Co.,Ltd. reported an annual EBITDA of 35.65 Million TWD in 2022, up 13.61% from previous year.
Welgene Biotech Co.,Ltd. reported an annual EBITDA of 39.12 Million TWD in 2021, down -45.06% from previous year.
Welgene Biotech Co.,Ltd. reported a quarterly EBITDA of 2.5 Million TWD for 2024 Q1, down -50.64% from previous quarter.
Welgene Biotech Co.,Ltd. reported a quarterly EBITDA of 4.93 Million TWD for 2023 Q4, down -21.39% from previous quarter.

Annual EBITDA Chart of Welgene Biotech Co.,Ltd. (2023 - 2014)

Historical Annual EBITDA of Welgene Biotech Co.,Ltd. (2023 - 2014)

Year	EBITDA	EBITDA Growth
2023	26.83 Million TWD	-28.38%
2022	35.65 Million TWD	13.61%
2021	39.12 Million TWD	-45.06%
2020	54.84 Million TWD	16.52%
2019	47.17 Million TWD	6.75%
2018	46.99 Million TWD	29.81%
2017	39.06 Million TWD	126.18%
2016	15.64 Million TWD	-49.97%
2015	31.27 Million TWD	-19.61%
2014	38.89 Million TWD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	6.26 Million TWD	190.69%
2024 Q1	2.5 Million TWD	-50.64%
2023 Q4	4.93 Million TWD	-21.39%
2023 FY	- TWD	-28.38%
2023 Q1	891 Thousand TWD	-76.64%
2023 Q2	13.44 Million TWD	1408.64%
2023 Q3	6.27 Million TWD	-53.33%
2022 Q2	22.07 Million TWD	30756.94%
2022 Q4	3.81 Million TWD	-61.25%
2022 Q3	9.84 Million TWD	-55.41%
2022 Q1	-72 Thousand TWD	-100.46%
2022 FY	- TWD	13.61%
2021 Q3	6.49 Million TWD	-37.52%
2021 FY	- TWD	-45.06%
2021 Q4	15.59 Million TWD	140.15%
2021 Q1	-1.1 Million TWD	-106.61%
2021 Q2	10.39 Million TWD	1043.38%
2020 FY	- TWD	16.52%
2020 Q4	16.67 Million TWD	2.87%
2020 Q3	16.21 Million TWD	4.7%
2020 Q2	15.48 Million TWD	76.81%
2020 Q1	8.75 Million TWD	-51.08%
2019 FY	- TWD	6.75%
2019 Q4	17.9 Million TWD	15.33%
2019 Q3	15.52 Million TWD	123.02%
2019 Q2	6.96 Million TWD	0.0%
2019 Q1	6.96 Million TWD	-61.61%
2018 Q2	5.03 Million TWD	0.0%
2018 FY	- TWD	29.81%
2018 Q1	5.03 Million TWD	-57.0%
2018 Q3	18.12 Million TWD	260.11%
2018 Q4	18.12 Million TWD	0.0%
2017 Q3	11.7 Million TWD	73.4%
2017 Q2	6.75 Million TWD	0.0%
2017 Q4	11.7 Million TWD	0.0%
2017 FY	- TWD	126.18%
2017 Q1	6.75 Million TWD	-18.0%
2016 FY	- TWD	-49.97%
2016 Q4	8.23 Million TWD	0.0%
2016 Q3	8.23 Million TWD	303.03%
2016 Q2	2.04 Million TWD	0.0%
2016 Q1	2.04 Million TWD	0.0%
2015 FY	- TWD	-19.61%
2014 FY	- TWD	0.0%

Peer EBITDA Comparison of Welgene Biotech Co.,Ltd.

Name	EBITDA	EBITDA Difference
BIONET Corp.	147.09 Million TWD	81.756%
DIVA Laboratories, Ltd.	100.31 Million TWD	73.248%
Genetics Generation Advancement Corp.	50.6 Million TWD	46.968%
Puriblood Medical Co., Ltd.	-44.01 Million TWD	160.97%
TFBS Bioscience Inc.	64.15 Million TWD	58.168%